FDA
-
-
-
-
-
-
-
Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021
-
-
-
-
-
322,345 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

